|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transcription/DNA
|
 |
|
Title:
|
 |
Structure of the DNA binding domains of nfat and foxp2 bound specifically to DNA.
|
|
Structure:
|
 |
5'- d(tp Tp Ap Gp Gp Ap Ap Ap Ap Tp Tp Tp Gp Tp Tp Tp Cp Ap Tp Ap Gp )-3'. Chain: a, c. Engineered: yes. 5'- d(ap Ap Cp Tp Ap Tp Gp Ap Ap Ap Cp Ap Ap Ap Tp Tp Tp Tp Cp Cp Tp )-3'. Chain: b, d.
|
|
Source:
|
 |
Synthetic: yes. Other_details: solid phase synthesis. Homo sapiens. Human. Organism_taxid: 9606. Gene: nfatc2, nfat1, nfatp. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008. Gene: foxp2.
|
|
Biol. unit:
|
 |
Octamer (from
)
|
|
Resolution:
|
 |
|
2.70Å
|
R-factor:
|
0.238
|
R-free:
|
0.287
|
|
|
Authors:
|
 |
Y.Wu,J.C.Stroud,M.Borde,D.L.Bates,L.Guo,A.Han,A.Rao,L.Chen
|
Key ref:
|
 |
Y.Wu
et al.
(2006).
FOXP3 controls regulatory T cell function through cooperation with NFAT.
Cell,
126,
375-387.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
22-Aug-05
|
Release date:
|
08-Aug-06
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
nucleus
|
1 term
|
 |
|
Biological process
|
regulation of transcription
|
2 terms
|
 |
|
Biochemical function
|
transcription factor activity
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Cell
126:375-387
(2006)
|
|
PubMed id:
|
|
|
|
|
| |
|
FOXP3 controls regulatory T cell function through cooperation with NFAT.
|
|
Y.Wu,
M.Borde,
V.Heissmeyer,
M.Feuerer,
A.D.Lapan,
J.C.Stroud,
D.L.Bates,
L.Guo,
A.Han,
S.F.Ziegler,
D.Mathis,
C.Benoist,
L.Chen,
A.Rao.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Antigen stimulation of immune cells activates the transcription factor NFAT, a
key regulator of T cell activation and anergy. NFAT forms cooperative complexes
with the AP-1 family of transcription factors and regulates T cell
activation-associated genes. Here we show that regulatory T cell (Treg) function
is mediated by an analogous cooperative complex of NFAT with the forkhead
transcription factor FOXP3, a lineage specification factor for Tregs. The
crystal structure of an NFAT:FOXP2:DNA complex reveals an extensive
protein-protein interaction interface between NFAT and FOXP2. Structure-guided
mutations of FOXP3, predicted to progressively disrupt its interaction with
NFAT, interfere in a graded manner with the ability of FOXP3 to repress
expression of the cytokine IL2, upregulate expression of the Treg markers CTLA4
and CD25, and confer suppressor function in a murine model of autoimmune
diabetes. Thus by switching transcriptional partners, NFAT converts the acute T
cell activation program into the suppressor program of Tregs.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. Protein-Protein Interactions between NFAT and FOXP
|
 |
Figure 8.
Figure 8. T Regulatory Function Requires the NFAT:FOXP3
Interface
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Cell
(2006,
126,
375-387)
copyright 2006.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Ma,
S.Qi,
L.Song,
Y.Hu,
H.Dun,
E.Massicotte,
M.Dupuis,
P.Daloze,
and
H.Chen
(2011).
Adoptive transfer of CD4(+)CD25(+) regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys.
|
| |
Int Immunopharmacol, 11,
618-629.
|
 |
|
|
|
|
 |
G.Cheng,
A.Yu,
and
T.R.Malek
(2011).
T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells.
|
| |
Immunol Rev, 241,
63-76.
|
 |
|
|
|
|
 |
H.Haiqi,
Z.Yong,
and
L.Yi
(2011).
Transcriptional regulation of Foxp3 in regulatory T cells.
|
| |
Immunobiology, 216,
678-685.
|
 |
|
|
|
|
 |
H.S.Bandukwala,
Y.Wu,
M.Feuerer,
Y.Chen,
B.Barboza,
S.Ghosh,
J.C.Stroud,
C.Benoist,
D.Mathis,
A.Rao,
and
L.Chen
(2011).
Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells.
|
| |
Immunity, 34,
479-491.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
I.Tsaur,
M.Gasser,
B.Aviles,
J.Lutz,
L.Lutz,
M.Grimm,
V.Lange,
K.Lopau,
U.Heemann,
C.T.Germer,
A.Chandraker,
and
A.M.Waaga-Gasser
(2011).
Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients.
|
| |
Kidney Int, 79,
1005-1012.
|
 |
|
|
|
|
 |
M.B.Werneck,
A.Vieira-de-Abreu,
R.Chammas,
and
J.P.Viola
(2011).
NFAT1 transcription factor is central in the regulation of tissue microenvironment for tumor metastasis.
|
| |
Cancer Immunol Immunother, 60,
537-546.
|
 |
|
|
|
|
 |
M.Beyer,
and
J.L.Schultze
(2011).
Plasticity of T(reg) cells: Is reprogramming of T(reg) cells possible in the presence of FOXP3?
|
| |
Int Immunopharmacol, 11,
555-560.
|
 |
|
|
|
|
 |
M.Redpath,
B.Xu,
L.C.van Kempen,
and
A.Spatz
(2011).
The dual role of the X-linked FoxP3 gene in human cancers.
|
| |
Mol Oncol, 5,
156-163.
|
 |
|
|
|
|
 |
M.Tone,
and
M.I.Greene
(2011).
Cooperative regulatory events and Foxp3 expression.
|
| |
Nat Immunol, 12,
14-16.
|
 |
|
|
|
|
 |
M.Vaeth,
T.Gogishvili,
T.Bopp,
M.Klein,
F.Berberich-Siebelt,
S.Gattenloehner,
A.Avots,
T.Sparwasser,
N.Grebe,
E.Schmitt,
T.Hünig,
E.Serfling,
and
J.Bodor
(2011).
Regulatory T cells facilitate the nuclear accumulation of inducible cAMP early repressor (ICER) and suppress nuclear factor of activated T cell c1 (NFATc1).
|
| |
Proc Natl Acad Sci U S A, 108,
2480-2485.
|
 |
|
|
|
|
 |
N.Ohkura,
M.Hamaguchi,
and
S.Sakaguchi
(2011).
FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents.
|
| |
Trends Pharmacol Sci, 32,
158-166.
|
 |
|
|
|
|
 |
N.Ohkura,
and
S.Sakaguchi
(2011).
Maturation of effector regulatory T cells.
|
| |
Nat Immunol, 12,
283-284.
|
 |
|
|
|
|
 |
W.F.Wong,
K.Kohu,
T.Chiba,
T.Sato,
and
M.Satake
(2011).
Interplay of transcription factors in T-cell differentiation and function: the role of Runx.
|
| |
Immunology, 132,
157-164.
|
 |
|
|
|
|
 |
Y.P.Chu,
C.H.Chang,
J.H.Shiu,
Y.T.Chang,
C.Y.Chen,
and
W.J.Chuang
(2011).
Solution structure and backbone dynamics of the DNA-binding domain of FOXP1: Insight into its domain swapping and DNA binding.
|
| |
Protein Sci, 20,
908-924.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Satou,
J.Yasunaga,
T.Zhao,
M.Yoshida,
P.Miyazato,
K.Takai,
K.Shimizu,
K.Ohshima,
P.L.Green,
N.Ohkura,
T.Yamaguchi,
M.Ono,
S.Sakaguchi,
and
M.Matsuoka
(2011).
HTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation In Vivo.
|
| |
PLoS Pathog, 7,
e1001274.
|
 |
|
|
|
|
 |
Z.Chen,
F.Lin,
Y.Gao,
Z.Li,
J.Zhang,
Y.Xing,
Z.Deng,
Z.Yao,
A.Tsun,
and
B.Li
(2011).
FOXP3 and RORγt: Transcriptional regulation of Treg and Th17.
|
| |
Int Immunopharmacol, 11,
536-542.
|
 |
|
|
|
|
 |
A.Planchart,
and
C.J.Mattingly
(2010).
2,3,7,8-Tetrachlorodibenzo-p-dioxin upregulates FoxQ1b in zebrafish jaw primordium.
|
| |
Chem Res Toxicol, 23,
480-487.
|
 |
|
|
|
|
 |
A.Sharabi,
S.Lapter,
and
E.Mozes
(2010).
Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
|
| |
J Autoimmun, 34,
87-95.
|
 |
|
|
|
|
 |
B.Kanwar,
D.Favre,
and
J.M.McCune
(2010).
Th17 and regulatory T cells: implications for AIDS pathogenesis.
|
| |
Curr Opin HIV AIDS, 5,
151-157.
|
 |
|
|
|
|
 |
B.Liu,
S.Tahk,
K.M.Yee,
G.Fan,
and
K.Shuai
(2010).
The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression.
|
| |
Science, 330,
521-525.
|
 |
|
|
|
|
 |
B.Y.Tsai,
J.L.Suen,
and
B.L.Chiang
(2010).
Lentiviral-mediated Foxp3 RNAi suppresses tumor growth of regulatory T cell-like leukemia in a murine tumor model.
|
| |
Gene Ther, 17,
972-979.
|
 |
|
|
|
|
 |
D.Busse,
M.de la Rosa,
K.Hobiger,
K.Thurley,
M.Flossdorf,
A.Scheffold,
and
T.Höfer
(2010).
Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments.
|
| |
Proc Natl Acad Sci U S A, 107,
3058-3063.
|
 |
|
|
|
|
 |
D.Hawiger,
Y.Y.Wan,
E.E.Eynon,
and
R.A.Flavell
(2010).
The transcription cofactor Hopx is required for regulatory T cell function in dendritic cell-mediated peripheral T cell unresponsiveness.
|
| |
Nat Immunol, 11,
962-968.
|
 |
|
|
|
|
 |
D.J.Jung,
D.H.Jin,
S.W.Hong,
J.E.Kim,
J.S.Shin,
D.Kim,
B.J.Cho,
Y.I.Hwang,
J.S.Kang,
and
W.J.Lee
(2010).
Foxp3 expression in p53-dependent DNA damage responses.
|
| |
J Biol Chem, 285,
7995-8002.
|
 |
|
|
|
|
 |
D.M.Tartar,
A.M.VanMorlan,
X.Wan,
F.B.Guloglu,
R.Jain,
C.L.Haymaker,
J.S.Ellis,
C.M.Hoeman,
J.A.Cascio,
M.Dhakal,
M.Oukka,
and
H.Zaghouani
(2010).
FoxP3+RORgammat+ T helper intermediates display suppressive function against autoimmune diabetes.
|
| |
J Immunol, 184,
3377-3385.
|
 |
|
|
|
|
 |
D.R.Littler,
M.Alvarez-Fernández,
A.Stein,
R.G.Hibbert,
T.Heidebrecht,
P.Aloy,
R.H.Medema,
and
A.Perrakis
(2010).
Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence.
|
| |
Nucleic Acids Res, 38,
4527-4538.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.A.Mittendorf,
and
P.Sharma
(2010).
Mechanisms of T-cell inhibition: implications for cancer immunotherapy.
|
| |
Expert Rev Vaccines, 9,
89.
|
 |
|
|
|
|
 |
E.Antiga,
C.C.Kretz,
R.Klembt,
D.Massi,
V.Ruland,
C.Stumpf,
G.Baroni,
M.Hartmann,
W.Hartschuh,
W.Volpi,
E.Del Bianco,
A.Enk,
P.Fabbri,
P.H.Krammer,
M.Caproni,
and
A.Kuhn
(2010).
Characterization of regulatory T cells in patients with dermatomyositis.
|
| |
J Autoimmun, 35,
342-350.
|
 |
|
|
|
|
 |
F.J.Quintana,
A.H.Iglesias,
M.F.Farez,
M.Caccamo,
E.J.Burns,
N.Kassam,
M.Oukka,
and
H.L.Weiner
(2010).
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
|
| |
PLoS One, 5,
e9478.
|
 |
|
|
|
|
 |
F.Martin,
S.Ladoire,
G.Mignot,
L.Apetoh,
and
F.Ghiringhelli
(2010).
Human FOXP3 and cancer.
|
| |
Oncogene, 29,
4121-4129.
|
 |
|
|
|
|
 |
G.Fu,
Y.Chen,
M.Yu,
A.Podd,
J.Schuman,
Y.He,
L.Di,
M.Yassai,
D.Haribhai,
P.E.North,
J.Gorski,
C.B.Williams,
D.Wang,
and
R.Wen
(2010).
Phospholipase C{gamma}1 is essential for T cell development, activation, and tolerance.
|
| |
J Exp Med, 207,
309-318.
|
 |
|
|
|
|
 |
G.M.Spudich,
and
X.M.Fernández-Suárez
(2010).
Touring Ensembl: a practical guide to genome browsing.
|
| |
BMC Genomics, 11,
295.
|
 |
|
|
|
|
 |
G.Xu,
L.Wang,
W.Chen,
F.Xue,
X.Bai,
L.Liang,
X.Shen,
M.Zhang,
D.Xia,
and
T.Liang
(2010).
Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation.
|
| |
Liver Transpl, 16,
357-363.
|
 |
|
|
|
|
 |
H.Katoh,
P.Zheng,
and
Y.Liu
(2010).
Signalling through FOXP3 as an X-linked tumor suppressor.
|
| |
Int J Biochem Cell Biol, 42,
1784-1787.
|
 |
|
|
|
|
 |
J.M.Choi,
J.H.Shin,
M.H.Sohn,
M.J.Harding,
J.H.Park,
Z.Tobiasova,
D.Y.Kim,
S.E.Maher,
W.J.Chae,
S.H.Park,
C.G.Lee,
S.K.Lee,
and
A.L.Bothwell
(2010).
Cell-permeable Foxp3 protein alleviates autoimmune disease associated with inflammatory bowel disease and allergic airway inflammation.
|
| |
Proc Natl Acad Sci U S A, 107,
18575-18580.
|
 |
|
|
|
|
 |
J.Su,
and
Y.C.Liu
(2010).
Foxp3 positive regulatory T cells: a functional regulation by the E3 ubiquitin ligase Itch.
|
| |
Semin Immunopathol, 32,
149-156.
|
 |
|
|
|
|
 |
J.Zhu,
H.Yamane,
and
W.E.Paul
(2010).
Differentiation of effector CD4 T cell populations (*).
|
| |
Annu Rev Immunol, 28,
445-489.
|
 |
|
|
|
|
 |
J.Zhu,
and
W.E.Paul
(2010).
Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors.
|
| |
Immunol Rev, 238,
247-262.
|
 |
|
|
|
|
 |
K.Araki,
S.Gangappa,
D.L.Dillehay,
B.T.Rouse,
C.P.Larsen,
and
R.Ahmed
(2010).
Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.
|
| |
J Exp Med, 207,
2355-2367.
|
 |
|
|
|
|
 |
K.Bocian,
J.Borysowski,
P.Wierzbicki,
J.Wyzgal,
D.Klosowska,
A.Bialoszewska,
L.Paczek,
A.Górski,
and
G.Korczak-Kowalska
(2010).
Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.
|
| |
Nephrol Dial Transplant, 25,
710-717.
|
 |
|
|
|
|
 |
K.Otsubo,
H.Kanegane,
I.Kobayashi,
and
T.Miyawaki
(2010).
[IPEX syndrome and human Treg cells].
|
| |
Nihon Rinsho Meneki Gakkai Kaishi, 33,
196-206.
|
 |
|
|
|
|
 |
K.Wing,
and
S.Sakaguchi
(2010).
Regulatory T cells exert checks and balances on self tolerance and autoimmunity.
|
| |
Nat Immunol, 11,
7.
|
 |
|
|
|
|
 |
L.S.Johnstone,
S.J.Graham,
and
M.A.Dziadek
(2010).
STIM proteins: integrators of signalling pathways in development, differentiation and disease.
|
| |
J Cell Mol Med, 14,
1890-1903.
|
 |
|
|
|
|
 |
M.A.Watanabe,
J.M.Oda,
M.K.Amarante,
and
J.Cesar Voltarelli
(2010).
Regulatory T cells and breast cancer: implications for immunopathogenesis.
|
| |
Cancer Metastasis Rev, 29,
569-579.
|
 |
|
|
|
|
 |
M.R.Müller,
and
A.Rao
(2010).
NFAT, immunity and cancer: a transcription factor comes of age.
|
| |
Nat Rev Immunol, 10,
645-656.
|
 |
|
|
|
|
 |
M.S.Sundrud,
and
M.A.Nolan
(2010).
Synergistic and combinatorial control of T cell activation and differentiation by transcription factors.
|
| |
Curr Opin Immunol, 22,
286-292.
|
 |
|
|
|
|
 |
M.Waterfield,
and
M.S.Anderson
(2010).
Clues to immune tolerance: the monogenic autoimmune syndromes.
|
| |
Ann N Y Acad Sci, 1214,
138-155.
|
 |
|
|
|
|
 |
N.Hermann-Kleiter,
and
G.Baier
(2010).
NFAT pulls the strings during CD4+ T helper cell effector functions.
|
| |
Blood, 115,
2989-2997.
|
 |
|
|
|
|
 |
N.Inoue,
M.Watanabe,
M.Morita,
R.Tomizawa,
T.Akamizu,
K.Tatsumi,
Y.Hidaka,
and
Y.Iwatani
(2010).
Association of functional polymorphisms related to the transcriptional level of FOXP3 with prognosis of autoimmune thyroid diseases.
|
| |
Clin Exp Immunol, 162,
402-406.
|
 |
|
|
|
|
 |
N.Jain,
H.Nguyen,
C.Chambers,
and
J.Kang
(2010).
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.
|
| |
Proc Natl Acad Sci U S A, 107,
1524-1528.
|
 |
|
|
|
|
 |
N.Ohkura,
and
S.Sakaguchi
(2010).
Regulatory T cells: roles of T cell receptor for their development and function.
|
| |
Semin Immunopathol, 32,
95.
|
 |
|
|
|
|
 |
P.Saas,
B.Gaugler,
and
S.Perruche
(2010).
Intravenous apoptotic cell infusion as a cell-based therapy toward improving hematopoietic cell transplantation outcome.
|
| |
Ann N Y Acad Sci, 1209,
118-126.
|
 |
|
|
|
|
 |
S.Ghosh,
S.B.Koralov,
I.Stevanovic,
M.S.Sundrud,
Y.Sasaki,
K.Rajewsky,
A.Rao,
and
M.R.Müller
(2010).
Hyperactivation of nuclear factor of activated T cells 1 (NFAT1) in T cells attenuates severity of murine autoimmune encephalomyelitis.
|
| |
Proc Natl Acad Sci U S A, 107,
15169-15174.
|
 |
|
|
|
|
 |
T.Fehr,
C.L.Lucas,
J.Kurtz,
T.Onoe,
G.Zhao,
T.Hogan,
C.Vallot,
A.Rao,
and
M.Sykes
(2010).
A CD8 T cell-intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo.
|
| |
Blood, 115,
1280-1287.
|
 |
|
|
|
|
 |
W.Chen,
and
J.E.Konkel
(2010).
TGF-beta and 'adaptive' Foxp3(+) regulatory T cells.
|
| |
J Mol Cell Biol, 2,
30-36.
|
 |
|
|
|
|
 |
W.H.Wang,
C.L.Jiang,
W.Yan,
Y.H.Zhang,
J.T.Yang,
C.Zhang,
B.Yan,
W.Zhang,
W.Han,
J.Z.Wang,
and
Y.Q.Zhang
(2010).
FOXP3 expression and clinical characteristics of hepatocellular carcinoma.
|
| |
World J Gastroenterol, 16,
5502-5509.
|
 |
|
|
|
|
 |
W.Hansen,
A.M.Westendorf,
T.Toepfer,
S.Mauel,
R.Geffers,
A.D.Gruber,
and
J.Buer
(2010).
Inflammation in vivo is modulated by GPR83 isoform-4 but not GPR83 isoform-1 expression in regulatory T cells.
|
| |
Genes Immun, 11,
357-361.
|
 |
|
|
|
|
 |
Y.Amasaki
(2010).
[Calcineurin inhibitors and calcineurin-NFAT system].
|
| |
Nihon Rinsho Meneki Gakkai Kaishi, 33,
249-261.
|
 |
|
|
|
|
 |
Y.Chen,
R.Dey,
and
L.Chen
(2010).
Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer.
|
| |
Structure, 18,
246-256.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Harada,
Y.Harada,
C.Elly,
G.Ying,
J.H.Paik,
R.A.DePinho,
and
Y.C.Liu
(2010).
Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells.
|
| |
J Exp Med, 207,
1381-1391.
|
 |
|
|
|
|
 |
A.D.Pardee,
A.K.Wesa,
and
W.J.Storkus
(2009).
Integrating costimulatory agonists to optimize immune-based cancer therapies.
|
| |
Immunotherapy, 1,
249-264.
|
 |
|
|
|
|
 |
A.Demirkiran,
V.D.Sewgobind,
J.van der Weijde,
A.Kok,
C.C.Baan,
J.Kwekkeboom,
H.W.Tilanus,
H.J.Metselaar,
and
L.J.van der Laan
(2009).
Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells.
|
| |
Transplantation, 87,
1062-1068.
|
 |
|
|
|
|
 |
A.J.Canonigo-Balancio,
C.Fos,
T.Prod'homme,
S.Bécart,
and
A.Altman
(2009).
SLAT/Def6 plays a critical role in the development of Th17 cell-mediated experimental autoimmune encephalomyelitis.
|
| |
J Immunol, 183,
7259-7267.
|
 |
|
|
|
|
 |
A.Kitoh,
M.Ono,
Y.Naoe,
N.Ohkura,
T.Yamaguchi,
H.Yaguchi,
I.Kitabayashi,
T.Tsukada,
T.Nomura,
Y.Miyachi,
I.Taniuchi,
and
S.Sakaguchi
(2009).
Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells.
|
| |
Immunity, 31,
609-620.
|
 |
|
|
|
|
 |
A.Rao
(2009).
Signaling to gene expression: calcium, calcineurin and NFAT.
|
| |
Nat Immunol, 10,
3-5.
|
 |
|
|
|
|
 |
A.Sharabi,
and
E.Mozes
(2009).
Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases.
|
| |
Immunotherapy, 1,
385-401.
|
 |
|
|
|
|
 |
C.A.Dendrou,
V.Plagnol,
E.Fung,
J.H.Yang,
K.Downes,
J.D.Cooper,
S.Nutland,
G.Coleman,
M.Himsworth,
M.Hardy,
O.Burren,
B.Healy,
N.M.Walker,
K.Koch,
W.H.Ouwehand,
J.R.Bradley,
N.J.Wareham,
J.A.Todd,
and
L.S.Wicker
(2009).
Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource.
|
| |
Nat Genet, 41,
1011-1015.
|
 |
|
|
|
|
 |
C.E.Egwuagu
(2009).
STAT3 in CD4+ T helper cell differentiation and inflammatory diseases.
|
| |
Cytokine, 47,
149-156.
|
 |
|
|
|
|
 |
C.Picard,
C.A.McCarl,
A.Papolos,
S.Khalil,
K.Lüthy,
C.Hivroz,
F.LeDeist,
F.Rieux-Laucat,
G.Rechavi,
A.Rao,
A.Fischer,
and
S.Feske
(2009).
STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity.
|
| |
N Engl J Med, 360,
1971-1980.
|
 |
|
|
|
|
 |
D.M.Tartar,
A.M.van Morlan,
and
H.Zaghouani
(2009).
T-regulatory/T-helper 17: promiscuous signals and fear of commitment.
|
| |
Immunotherapy, 1,
27-29.
|
 |
|
|
|
|
 |
D.Rudra,
T.Egawa,
M.M.Chong,
P.Treuting,
D.R.Littman,
and
A.Y.Rudensky
(2009).
Runx-CBFbeta complexes control expression of the transcription factor Foxp3 in regulatory T cells.
|
| |
Nat Immunol, 10,
1170-1177.
|
 |
|
|
|
|
 |
E.F.de Zoeten,
I.Lee,
L.Wang,
C.Chen,
G.Ge,
A.D.Wells,
W.W.Hancock,
and
E.Ozkaynak
(2009).
Foxp3 processing by proprotein convertases and control of regulatory T cell function.
|
| |
J Biol Chem, 284,
5709-5716.
|
 |
|
|
|
|
 |
F.Pan,
H.Yu,
E.V.Dang,
J.Barbi,
X.Pan,
J.F.Grosso,
D.Jinasena,
S.M.Sharma,
E.M.McCadden,
D.Getnet,
C.G.Drake,
J.O.Liu,
M.C.Ostrowski,
and
D.M.Pardoll
(2009).
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells.
|
| |
Science, 325,
1142-1146.
|
 |
|
|
|
|
 |
G.Driessens,
J.Kline,
and
T.F.Gajewski
(2009).
Costimulatory and coinhibitory receptors in anti-tumor immunity.
|
| |
Immunol Rev, 229,
126-144.
|
 |
|
|
|
|
 |
H.Ait-Oufella,
S.Taleb,
Z.Mallat,
and
A.Tedgui
(2009).
Cytokine network and T cell immunity in atherosclerosis.
|
| |
Semin Immunopathol, 31,
23-33.
|
 |
|
|
|
|
 |
I.Baine,
B.T.Abe,
and
F.Macian
(2009).
Regulation of T-cell tolerance by calcium/NFAT signaling.
|
| |
Immunol Rev, 231,
225-240.
|
 |
|
|
|
|
 |
J.C.Crispín,
and
G.C.Tsokos
(2009).
Transcriptional regulation of IL-2 in health and autoimmunity.
|
| |
Autoimmun Rev, 8,
190-195.
|
 |
|
|
|
|
 |
J.E.Smith-Garvin,
G.A.Koretzky,
and
M.S.Jordan
(2009).
T cell activation.
|
| |
Annu Rev Immunol, 27,
591-619.
|
 |
|
|
|
|
 |
J.Hong,
H.Li,
M.Chen,
Y.C.Zang,
S.M.Skinner,
J.M.Killian,
and
J.Z.Zhang
(2009).
Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis.
|
| |
Int Immunol, 21,
1329-1340.
|
 |
|
|
|
|
 |
J.Nolting,
C.Daniel,
S.Reuter,
C.Stuelten,
P.Li,
H.Sucov,
B.G.Kim,
J.J.Letterio,
K.Kretschmer,
H.J.Kim,
and
H.von Boehmer
(2009).
Retinoic acid can enhance conversion of naive into regulatory T cells independently of secreted cytokines.
|
| |
J Exp Med, 206,
2131-2139.
|
 |
|
|
|
|
 |
K.Nakamura,
M.Miki,
Y.Mizoguchi,
S.Karakawa,
T.Sato,
and
M.Kobayashi
(2009).
Deficiency of regulatory T cells in children with autoimmune neutropenia.
|
| |
Br J Haematol, 145,
642-647.
|
 |
|
|
|
|
 |
K.P.Koh,
M.S.Sundrud,
and
A.Rao
(2009).
Domain requirements and sequence specificity of DNA binding for the forkhead transcription factor FOXP3.
|
| |
PLoS One, 4,
e8109.
|
 |
|
|
|
|
 |
L.Bäckdahl,
A.Bushell,
and
S.Beck
(2009).
Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation.
|
| |
Int J Biochem Cell Biol, 41,
176-184.
|
 |
|
|
|
|
 |
L.Bruno,
L.Mazzarella,
M.Hoogenkamp,
A.Hertweck,
B.S.Cobb,
S.Sauer,
S.Hadjur,
M.Leleu,
Y.Naoe,
J.C.Telfer,
C.Bonifer,
I.Taniuchi,
A.G.Fisher,
and
M.Merkenschlager
(2009).
Runx proteins regulate Foxp3 expression.
|
| |
J Exp Med, 206,
2329-2337.
|
 |
|
|
|
|
 |
L.F.Lu,
and
A.Rudensky
(2009).
Molecular orchestration of differentiation and function of regulatory T cells.
|
| |
Genes Dev, 23,
1270-1282.
|
 |
|
|
|
|
 |
L.Wang,
E.F.de Zoeten,
M.I.Greene,
and
W.W.Hancock
(2009).
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.
|
| |
Nat Rev Drug Discov, 8,
969-981.
|
 |
|
|
|
|
 |
M.López-Hoyos,
D.S.Segundo,
G.Fernández-Fresnedo,
M.J.Marín,
V.González-Martín,
and
M.Arias
(2009).
Regulatory T cells in renal transplantation and modulation by immunosuppression.
|
| |
Transplantation, 88,
S31-S39.
|
 |
|
|
|
|
 |
M.Mancini,
and
A.Toker
(2009).
NFAT proteins: emerging roles in cancer progression.
|
| |
Nat Rev Cancer, 9,
810-820.
|
 |
|
|
|
|
 |
M.Oh-hora
(2009).
Calcium signaling in the development and function of T-lineage cells.
|
| |
Immunol Rev, 231,
210-224.
|
 |
|
|
|
|
 |
M.Oh-hora,
and
A.Rao
(2009).
The calcium/NFAT pathway: role in development and function of regulatory T cells.
|
| |
Microbes Infect, 11,
612-619.
|
 |
|
|
|
|
 |
M.Paolino,
and
J.M.Penninger
(2009).
E3 ubiquitin ligases in T-cell tolerance.
|
| |
Eur J Immunol, 39,
2337-2344.
|
 |
|
|
|
|
 |
M.Probst-Kepper,
R.Geffers,
A.Kröger,
N.Viegas,
C.Erck,
H.J.Hecht,
H.Lünsdorf,
R.Roubin,
D.Moharregh-Khiabani,
K.Wagner,
F.Ocklenburg,
A.Jeron,
H.Garritsen,
T.P.Arstila,
E.Kekäläinen,
R.Balling,
H.Hauser,
J.Buer,
and
S.Weiss
(2009).
GARP: a key receptor controlling FOXP3 in human regulatory T cells.
|
| |
J Cell Mol Med, 13,
3343-3357.
|
 |
|
|
|
|
 |
M.V.Sitkovsky
(2009).
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.
|
| |
Trends Immunol, 30,
102-108.
|
 |
|
|
|
|
 |
N.Jain,
H.Nguyen,
R.H.Friedline,
N.Malhotra,
M.Brehm,
M.Koyanagi,
M.Bix,
J.A.Cooper,
C.A.Chambers,
and
J.Kang
(2009).
Cutting edge: Dab2 is a FOXP3 target gene required for regulatory T cell function.
|
| |
J Immunol, 183,
4192-4196.
|
 |
|
|
|
|
 |
N.Soto-Nieves,
I.Puga,
B.T.Abe,
S.Bandyopadhyay,
I.Baine,
A.Rao,
and
F.Macian
(2009).
Transcriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance.
|
| |
J Exp Med, 206,
867-876.
|
 |
|
|
|
|
 |
R.Bommireddy,
O.F.Bueno,
J.Martin,
I.Ormsby,
H.Chen,
C.Gard,
J.D.Molkentin,
G.P.Boivin,
G.F.Babcock,
and
T.Doetschman
(2009).
Calcineurin deficiency decreases inflammatory lesions in transforming growth factor beta1-deficient mice.
|
| |
Clin Exp Immunol, 158,
317-324.
|
 |
|
|
|
|
 |
R.K.Mailer,
K.Falk,
and
O.Rötzschke
(2009).
Absence of leucine zipper in the natural FOXP3Delta2Delta7 isoform does not affect dimerization but abrogates suppressive capacity.
|
| |
PLoS One, 4,
e6104.
|
 |
|
|
|
|
 |
S.F.Ziegler,
and
J.H.Buckner
(2009).
FOXP3 and the regulation of Treg/Th17 differentiation.
|
| |
Microbes Infect, 11,
594-598.
|
 |
|
|
|
|
 |
S.Feske
(2009).
ORAI1 and STIM1 deficiency in human and mice: roles of store-operated Ca2+ entry in the immune system and beyond.
|
| |
Immunol Rev, 231,
189-209.
|
 |
|
|
|
|
 |
S.Klunker,
M.M.Chong,
P.Y.Mantel,
O.Palomares,
C.Bassin,
M.Ziegler,
B.Rückert,
F.Meiler,
M.Akdis,
D.R.Littman,
and
C.A.Akdis
(2009).
Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells.
|
| |
J Exp Med, 206,
2701-2715.
|
 |
|
|
|
|
 |
S.Sakaguchi,
K.Wing,
and
T.Yamaguchi
(2009).
Dynamics of peripheral tolerance and immune regulation mediated by Treg.
|
| |
Eur J Immunol, 39,
2331-2336.
|
 |
|
|
|
|
 |
S.Sakaguchi,
K.Wing,
Y.Onishi,
P.Prieto-Martin,
and
T.Yamaguchi
(2009).
Regulatory T cells: how do they suppress immune responses?
|
| |
Int Immunol, 21,
1105-1111.
|
 |
|
|
|
|
 |
T.A.Chatila
(2009).
Regulatory T cells: key players in tolerance and autoimmunity.
|
| |
Endocrinol Metab Clin North Am, 38,
265.
|
 |
|
|
|
|
 |
T.Bollinger,
A.Bollinger,
L.Skrum,
S.Dimitrov,
T.Lange,
and
W.Solbach
(2009).
Sleep-dependent activity of T cells and regulatory T cells.
|
| |
Clin Exp Immunol, 155,
231-238.
|
 |
|
|
|
|
 |
T.K.Hendrikx,
E.A.van Gurp,
W.M.Mol,
W.Schoordijk,
V.D.Sewgobind,
J.N.Ijzermans,
W.Weimar,
and
C.C.Baan
(2009).
End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells.
|
| |
Nephrol Dial Transplant, 24,
1969-1978.
|
 |
|
|
|
|
 |
T.R.Torgerson,
A.Genin,
C.Chen,
M.Zhang,
B.Zhou,
S.Añover-Sombke,
M.B.Frank,
I.Dozmorov,
E.Ocheltree,
P.Kulmala,
M.Centola,
H.D.Ochs,
A.D.Wells,
and
R.Q.Cron
(2009).
FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression.
|
| |
J Immunol, 183,
907-915.
|
 |
|
|
|
|
 |
W.W.Hancock,
and
E.Ozkaynak
(2009).
Three distinct domains contribute to nuclear transport of murine Foxp3.
|
| |
PLoS One, 4,
e7890.
|
 |
|
|
|
|
 |
X.Bi,
Y.Suzuki,
H.Gatanaga,
and
S.Oka
(2009).
High frequency and proliferation of CD4(+)FOXP3(+) Treg in HIV-1-infected patients with low CD4 counts.
|
| |
Eur J Immunol, 39,
301-309.
|
 |
|
|
|
|
 |
Y.Baba,
and
T.Kurosaki
(2009).
Physiological function and molecular basis of STIM1-mediated calcium entry in immune cells.
|
| |
Immunol Rev, 231,
174-188.
|
 |
|
|
|
|
 |
Y.Yamano,
N.Araya,
T.Sato,
A.Utsunomiya,
K.Azakami,
D.Hasegawa,
T.Izumi,
H.Fujita,
S.Aratani,
N.Yagishita,
R.Fujii,
K.Nishioka,
S.Jacobson,
and
T.Nakajima
(2009).
Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.
|
| |
PLoS One, 4,
e6517.
|
 |
|
|
|
|
 |
Z.Shen,
L.Chen,
F.Hao,
and
J.Wu
(2009).
Transcriptional regulation of Foxp3 gene: multiple signal pathways on the road.
|
| |
Med Res Rev, 29,
742-766.
|
 |
|
|
|
|
 |
A.A.Vandenbark,
N.E.Culbertson,
R.M.Bartholomew,
J.Huan,
M.Agotsch,
D.LaTocha,
V.Yadav,
M.Mass,
R.Whitham,
J.Lovera,
J.Milano,
G.Theofan,
Y.K.Chou,
H.Offner,
and
D.N.Bourdette
(2008).
Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.
|
| |
Immunology, 123,
66-78.
|
 |
|
|
|
|
 |
A.Demirkiran,
T.K.Hendrikx,
C.C.Baan,
and
L.J.van der Laan
(2008).
Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting?
|
| |
Transplantation, 85,
783-789.
|
 |
|
|
|
|
 |
A.Mor,
G.Keren,
Y.Kloog,
and
J.George
(2008).
N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells.
|
| |
Eur J Immunol, 38,
1493-1502.
|
 |
|
|
|
|
 |
A.Suto,
D.Kashiwakuma,
S.Kagami,
K.Hirose,
N.Watanabe,
K.Yokote,
Y.Saito,
T.Nakayama,
M.J.Grusby,
I.Iwamoto,
and
H.Nakajima
(2008).
Development and characterization of IL-21-producing CD4+ T cells.
|
| |
J Exp Med, 205,
1369-1379.
|
 |
|
|
|
|
 |
B.Li,
and
M.I.Greene
(2008).
Special regulatory T-cell review: FOXP3 biochemistry in regulatory T cells--how diverse signals regulate suppression.
|
| |
Immunology, 123,
17-19.
|
 |
|
|
|
|
 |
C.Jandus,
G.Bioley,
D.E.Speiser,
and
P.Romero
(2008).
Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood.
|
| |
Cancer Immunol Immunother, 57,
1795-1805.
|
 |
|
|
|
|
 |
D.L.Bates,
K.K.Barthel,
Y.Wu,
R.Kalhor,
J.C.Stroud,
M.J.Giffin,
and
L.Chen
(2008).
Crystal structure of NFAT bound to the HIV-1 LTR tandem kappaB enhancer element.
|
| |
Structure, 16,
684-694.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.Martins,
and
K.Calame
(2008).
Regulation and functions of Blimp-1 in T and B lymphocytes.
|
| |
Annu Rev Immunol, 26,
133-169.
|
 |
|
|
|
|
 |
G.Matarese,
V.De Rosa,
and
A.La Cava
(2008).
Regulatory CD4 T cells: sensing the environment.
|
| |
Trends Immunol, 29,
12-17.
|
 |
|
|
|
|
 |
G.N.Huang,
D.L.Huso,
S.Bouyain,
J.Tu,
K.A.McCorkell,
M.J.May,
Y.Zhu,
M.Lutz,
S.Collins,
M.Dehoff,
S.Kang,
K.Whartenby,
J.Powell,
D.Leahy,
and
P.F.Worley
(2008).
NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins.
|
| |
Science, 319,
476-481.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.von Boehmer,
and
J.Nolting
(2008).
What turns on Foxp3?
|
| |
Nat Immunol, 9,
121-122.
|
 |
|
|
|
|
 |
I.Apostolou,
P.Verginis,
K.Kretschmer,
J.Polansky,
J.Hühn,
and
H.von Boehmer
(2008).
Peripherally induced treg: mode, stability, and role in specific tolerance.
|
| |
J Clin Immunol, 28,
619-624.
|
 |
|
|
|
|
 |
J.A.Hill,
J.A.Hall,
C.M.Sun,
Q.Cai,
N.Ghyselinck,
P.Chambon,
Y.Belkaid,
D.Mathis,
and
C.Benoist
(2008).
Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells.
|
| |
Immunity, 29,
758-770.
|
 |
|
|
|
|
 |
J.H.Buckner,
and
S.F.Ziegler
(2008).
Functional analysis of FOXP3.
|
| |
Ann N Y Acad Sci, 1143,
151-169.
|
 |
|
|
|
|
 |
J.H.Niess
(2008).
Role of mucosal dendritic cells in inflammatory bowel disease.
|
| |
World J Gastroenterol, 14,
5138-5148.
|
 |
|
|
|
|
 |
J.Honkanen,
S.Skarsvik,
M.Knip,
and
O.Vaarala
(2008).
Poor in vitro induction of FOXP3 and ICOS in type 1 cytokine environment activated T-cells from children with type 1 diabetes.
|
| |
Diabetes Metab Res Rev, 24,
635-641.
|
 |
|
|
|
|
 |
J.L.Coombes,
and
F.Powrie
(2008).
Dendritic cells in intestinal immune regulation.
|
| |
Nat Rev Immunol, 8,
435-446.
|
 |
|
|
|
|
 |
J.V.Falvo,
C.H.Lin,
A.V.Tsytsykova,
P.K.Hwang,
D.Thanos,
A.E.Goldfeld,
and
T.Maniatis
(2008).
A dimer-specific function of the transcription factor NFATp.
|
| |
Proc Natl Acad Sci U S A, 105,
19637-19642.
|
 |
|
|
|
|
 |
J.Zhu,
and
W.E.Paul
(2008).
CD4 T cells: fates, functions, and faults.
|
| |
Blood, 112,
1557-1569.
|
 |
|
|
|
|
 |
K.G.Andersen,
T.Butcher,
and
A.G.Betz
(2008).
Specific immunosuppression with inducible Foxp3-transduced polyclonal T cells.
|
| |
PLoS Biol, 6,
e276.
|
 |
|
|
|
|
 |
K.Ichiyama,
H.Yoshida,
Y.Wakabayashi,
T.Chinen,
K.Saeki,
M.Nakaya,
G.Takaesu,
S.Hori,
A.Yoshimura,
and
T.Kobayashi
(2008).
Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat.
|
| |
J Biol Chem, 283,
17003-17008.
|
 |
|
|
|
|
 |
K.J.Oestreich,
H.Yoon,
R.Ahmed,
and
J.M.Boss
(2008).
NFATc1 regulates PD-1 expression upon T cell activation.
|
| |
J Immunol, 181,
4832-4839.
|
 |
|
|
|
|
 |
K.M.Elias,
A.Laurence,
T.S.Davidson,
G.Stephens,
Y.Kanno,
E.M.Shevach,
and
J.J.O'Shea
(2008).
Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway.
|
| |
Blood, 111,
1013-1020.
|
 |
|
|
|
|
 |
K.Venuprasad,
H.Huang,
Y.Harada,
C.Elly,
M.Subramaniam,
T.Spelsberg,
J.Su,
and
Y.C.Liu
(2008).
The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1.
|
| |
Nat Immunol, 9,
245-253.
|
 |
|
|
|
|
 |
K.Wing,
Y.Onishi,
P.Prieto-Martin,
T.Yamaguchi,
M.Miyara,
Z.Fehervari,
T.Nomura,
and
S.Sakaguchi
(2008).
CTLA-4 control over Foxp3+ regulatory T cell function.
|
| |
Science, 322,
271-275.
|
 |
|
|
|
|
 |
L.Zhou,
J.E.Lopes,
M.M.Chong,
I.I.Ivanov,
R.Min,
G.D.Victora,
Y.Shen,
J.Du,
Y.P.Rubtsov,
A.Y.Rudensky,
S.F.Ziegler,
and
D.R.Littman
(2008).
TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.
|
| |
Nature, 453,
236-240.
|
 |
|
|
|
|
 |
M.E.Pipkin,
and
S.Monticelli
(2008).
Genomics and the immune system.
|
| |
Immunology, 124,
23-32.
|
 |
|
|
|
|
 |
M.J.Welters,
S.J.Piersma,
and
S.H.van der Burg
(2008).
T-regulatory cells in tumour-specific vaccination strategies.
|
| |
Expert Opin Biol Ther, 8,
1365-1379.
|
 |
|
|
|
|
 |
M.Kasprzycka,
Q.Zhang,
A.Witkiewicz,
M.Marzec,
M.Potoczek,
X.Liu,
H.Y.Wang,
M.Milone,
S.Basu,
J.Mauger,
J.K.Choi,
J.T.Abrams,
J.S.Hou,
A.H.Rook,
E.Vonderheid,
A.Woetmann,
N.Odum,
and
M.A.Wasik
(2008).
Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.
|
| |
J Immunol, 181,
2506-2512.
|
 |
|
|
|
|
 |
M.Nagar,
H.Vernitsky,
Y.Cohen,
D.Dominissini,
Y.Berkun,
G.Rechavi,
N.Amariglio,
and
I.Goldstein
(2008).
Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ T cells.
|
| |
Int Immunol, 20,
1041-1055.
|
 |
|
|
|
|
 |
M.Oh-Hora,
M.Yamashita,
P.G.Hogan,
S.Sharma,
E.Lamperti,
W.Chung,
M.Prakriya,
S.Feske,
and
A.Rao
(2008).
Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance.
|
| |
Nat Immunol, 9,
432-443.
|
 |
|
|
|
|
 |
M.Oh-hora,
and
A.Rao
(2008).
Calcium signaling in lymphocytes.
|
| |
Curr Opin Immunol, 20,
250-258.
|
 |
|
|
|
|
 |
N.M.Tsuji,
and
A.Kosaka
(2008).
Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells.
|
| |
Trends Immunol, 29,
532-540.
|
 |
|
|
|
|
 |
N.Selliah,
M.Zhang,
S.White,
P.Zoltick,
B.E.Sawaya,
T.H.Finkel,
and
R.Q.Cron
(2008).
FOXP3 inhibits HIV-1 infection of CD4 T-cells via inhibition of LTR transcriptional activity.
|
| |
Virology, 381,
161-167.
|
 |
|
|
|
|
 |
P.Pandiyan,
and
M.J.Lenardo
(2008).
The control of CD4+CD25+Foxp3+ regulatory T cell survival.
|
| |
Biol Direct, 3,
6.
|
 |
|
|
|
|
 |
Q.Jiang,
L.Zhang,
R.Wang,
J.Jeffrey,
M.L.Washburn,
D.Brouwer,
S.Barbour,
G.I.Kovalev,
D.Unutmaz,
and
L.Su
(2008).
FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo.
|
| |
Blood, 112,
2858-2868.
|
 |
|
|
|
|
 |
R.Zeiser,
D.B.Leveson-Gower,
E.A.Zambricki,
N.Kambham,
A.Beilhack,
J.Loh,
J.Z.Hou,
and
R.S.Negrin
(2008).
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.
|
| |
Blood, 111,
453-462.
|
 |
|
|
|
|
 |
R.Zeiser,
and
R.S.Negrin
(2008).
Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy.
|
| |
Cell Cycle, 7,
458-462.
|
 |
|
|
|
|
 |
S.Basu,
T.Golovina,
T.Mikheeva,
C.H.June,
and
J.L.Riley
(2008).
Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.
|
| |
J Immunol, 180,
5794-5798.
|
 |
|
|
|
|
 |
S.E.Allan,
A.N.Alstad,
N.Merindol,
N.K.Crellin,
M.Amendola,
R.Bacchetta,
L.Naldini,
M.G.Roncarolo,
H.Soudeyns,
and
M.K.Levings
(2008).
Generation of Potent and Stable Human CD4(+) T Regulatory Cells by Activation-independent Expression of FOXP3.
|
| |
Mol Ther, 16,
194-202.
|
 |
|
|
|
|
 |
S.E.Allan,
G.X.Song-Zhao,
T.Abraham,
A.N.McMurchy,
and
M.K.Levings
(2008).
Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3.
|
| |
Eur J Immunol, 38,
3282-3289.
|
 |
|
|
|
|
 |
S.Gupta,
S.Manicassamy,
C.Vasu,
A.Kumar,
W.Shang,
and
Z.Sun
(2008).
Differential requirement of PKC-theta in the development and function of natural regulatory T cells.
|
| |
Mol Immunol, 46,
213-224.
|
 |
|
|
|
|
 |
S.Pai,
and
R.Thomas
(2008).
Immune deficiency or hyperactivity-Nf-kappab illuminates autoimmunity.
|
| |
J Autoimmun, 31,
245-251.
|
 |
|
|
|
|
 |
S.Sakaguchi,
T.Yamaguchi,
T.Nomura,
and
M.Ono
(2008).
Regulatory T cells and immune tolerance.
|
| |
Cell, 133,
775-787.
|
 |
|
|
|
|
 |
S.Sarkar,
and
D.A.Fox
(2008).
Regulatory T cells in rheumatoid arthritis.
|
| |
Curr Rheumatol Rep, 10,
405-412.
|
 |
|
|
|
|
 |
S.Taleb,
A.Tedgui,
and
Z.Mallat
(2008).
Regulatory T-cell immunity and its relevance to atherosclerosis.
|
| |
J Intern Med, 263,
489-499.
|
 |
|
|
|
|
 |
S.Xiao,
H.Jin,
T.Korn,
S.M.Liu,
M.Oukka,
B.Lim,
and
V.K.Kuchroo
(2008).
Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression.
|
| |
J Immunol, 181,
2277-2284.
|
 |
|
|
|
|
 |
T.Aarts-Riemens,
M.E.Emmelot,
L.F.Verdonck,
and
T.Mutis
(2008).
Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.
|
| |
Eur J Immunol, 38,
1381-1390.
|
 |
|
|
|
|
 |
T.C.Shih,
S.Y.Hsieh,
Y.Y.Hsieh,
T.C.Chen,
C.Y.Yeh,
C.J.Lin,
D.Y.Lin,
and
C.T.Chiu
(2008).
Aberrant activation of nuclear factor of activated T cell 2 in lamina propria mononuclear cells in ulcerative colitis.
|
| |
World J Gastroenterol, 14,
1759-1767.
|
 |
|
|
|
|
 |
T.Dasu,
J.E.Qualls,
H.Tuna,
C.Raman,
D.A.Cohen,
and
S.Bondada
(2008).
CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells.
|
| |
Immunol Lett, 119,
103-113.
|
 |
|
|
|
|
 |
T.Obsil,
and
V.Obsilova
(2008).
Structure/function relationships underlying regulation of FOXO transcription factors.
|
| |
Oncogene, 27,
2263-2275.
|
 |
|
|
|
|
 |
T.R.Malek
(2008).
The biology of interleukin-2.
|
| |
Annu Rev Immunol, 26,
453-479.
|
 |
|
|
|
|
 |
V.Karanikas,
M.Speletas,
M.Zamanakou,
F.Kalala,
G.Loules,
T.Kerenidi,
A.K.Barda,
K.I.Gourgoulianis,
and
A.E.Germenis
(2008).
Foxp3 expression in human cancer cells.
|
| |
J Transl Med, 6,
19.
|
 |
|
|
|
|
 |
W.Fujimaki,
N.Takahashi,
K.Ohnuma,
M.Nagatsu,
H.Kurosawa,
S.Yoshida,
N.H.Dang,
T.Uchiyama,
and
C.Morimoto
(2008).
Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood.
|
| |
Clin Dev Immunol, 2008,
305859.
|
 |
|
|
|
|
 |
X.Feng,
S.Kajigaya,
E.E.Solomou,
K.Keyvanfar,
X.Xu,
N.Raghavachari,
P.J.Munson,
T.M.Herndon,
J.Chen,
and
N.S.Young
(2008).
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.
|
| |
Blood, 111,
3675-3683.
|
 |
|
|
|
|
 |
Y.Ding,
S.Shen,
A.C.Lino,
M.A.Curotto de Lafaille,
and
J.J.Lafaille
(2008).
Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells.
|
| |
Nat Med, 14,
162-169.
|
 |
|
|
|
|
 |
Y.Tone,
K.Furuuchi,
Y.Kojima,
M.L.Tykocinski,
M.I.Greene,
and
M.Tone
(2008).
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer.
|
| |
Nat Immunol, 9,
194-202.
|
 |
|
|
|
|
 |
Y.Zheng,
C.N.Manzotti,
F.Burke,
L.Dussably,
O.Qureshi,
L.S.Walker,
and
D.M.Sansom
(2008).
Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3.
|
| |
J Immunol, 181,
1683-1691.
|
 |
|
|
|
|
 |
Z.A.Rana,
K.Gundersen,
and
A.Buonanno
(2008).
Activity-dependent repression of muscle genes by NFAT.
|
| |
Proc Natl Acad Sci U S A, 105,
5921-5926.
|
 |
|
|
|
|
 |
Z.Popmihajlov,
and
K.A.Smith
(2008).
Negative feedback regulation of T cells via interleukin-2 and FOXP3 reciprocity.
|
| |
PLoS ONE, 3,
e1581.
|
 |
|
|
|
|
 |
Z.Zhou,
X.Song,
B.Li,
and
M.I.Greene
(2008).
FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity.
|
| |
Immunol Res, 42,
19-28.
|
 |
|
|
|
|
 |
A.Brüstle,
S.Heink,
M.Huber,
C.Rosenplänter,
C.Stadelmann,
P.Yu,
E.Arpaia,
T.W.Mak,
T.Kamradt,
and
M.Lohoff
(2007).
The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4.
|
| |
Nat Immunol, 8,
958-966.
|
 |
|
|
|
|
 |
A.Marson,
K.Kretschmer,
G.M.Frampton,
E.S.Jacobsen,
J.K.Polansky,
K.D.MacIsaac,
S.S.Levine,
E.Fraenkel,
H.von Boehmer,
and
R.A.Young
(2007).
Foxp3 occupancy and regulation of key target genes during T-cell stimulation.
|
| |
Nature, 445,
931-935.
|
 |
|
|
|
|
 |
B.Li,
A.Samanta,
X.Song,
K.T.Iacono,
K.Bembas,
R.Tao,
S.Basu,
J.L.Riley,
W.W.Hancock,
Y.Shen,
S.J.Saouaf,
and
M.I.Greene
(2007).
FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression.
|
| |
Proc Natl Acad Sci U S A, 104,
4571-4576.
|
 |
|
|
|
|
 |
C.A.Chougnet,
and
G.M.Shearer
(2007).
Regulatory T cells (Treg) and HIV/AIDS: summary of the September 7-8, 2006 workshop.
|
| |
AIDS Res Hum Retroviruses, 23,
945-952.
|
 |
|
|
|
|
 |
C.A.Coleman,
M.C.Muller-Trutwin,
C.Apetrei,
and
I.Pandrea
(2007).
T regulatory cells: aid or hindrance in the clearance of disease?
|
| |
J Cell Mol Med, 11,
1291-1325.
|
 |
|
|
|
|
 |
C.C.Goodnow
(2007).
Multistep pathogenesis of autoimmune disease.
|
| |
Cell, 130,
25-35.
|
 |
|
|
|
|
 |
D.Holmes,
G.Knudsen,
S.Mackey-Cushman,
and
L.Su
(2007).
FoxP3 enhances HIV-1 gene expression by modulating NFkappaB occupancy at the long terminal repeat in human T cells.
|
| |
J Biol Chem, 282,
15973-15980.
|
 |
|
|
|
|
 |
D.J.Campbell,
and
S.F.Ziegler
(2007).
FOXP3 modifies the phenotypic and functional properties of regulatory T cells.
|
| |
Nat Rev Immunol, 7,
305-310.
|
 |
|
|
|
|
 |
D.Q.Tran,
H.Ramsey,
and
E.M.Shevach
(2007).
Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.
|
| |
Blood, 110,
2983-2990.
|
 |
|
|
|
|
 |
E.E.Solomou,
K.Rezvani,
S.Mielke,
D.Malide,
K.Keyvanfar,
V.Visconte,
S.Kajigaya,
A.J.Barrett,
and
N.S.Young
(2007).
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia.
|
| |
Blood, 110,
1603-1606.
|
 |
|
|
|
|
 |
E.K.Koltsova,
D.L.Wiest,
and
T.P.Vavilova
(2007).
Transcription factors NFAT2 and Egr1 cooperatively regulate the maturation of T-lymphoma in vitro.
|
| |
Biochemistry (Mosc), 72,
954-961.
|
 |
|
|
|
|
 |
E.V.Rothenberg
(2007).
Cell lineage regulators in B and T cell development.
|
| |
Nat Immunol, 8,
441-444.
|
 |
|
|
|
|
 |
F.Rebeaud,
S.Hailfinger,
and
M.Thome
(2007).
Dlgh1 and Carma1 MAGUK proteins contribute to signal specificity downstream of TCR activation.
|
| |
Trends Immunol, 28,
196-200.
|
 |
|
|
|
|
 |
H.B.Koon,
G.C.Ippolito,
A.H.Banham,
and
P.W.Tucker
(2007).
FOXP1: a potential therapeutic target in cancer.
|
| |
Expert Opin Ther Targets, 11,
955-965.
|
 |
|
|
|
|
 |
H.D.Ochs,
E.Gambineri,
and
T.R.Torgerson
(2007).
IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity.
|
| |
Immunol Res, 38,
112-121.
|
 |
|
|
|
|
 |
H.Hu,
I.Djuretic,
M.S.Sundrud,
and
A.Rao
(2007).
Transcriptional partners in regulatory T cells: Foxp3, Runx and NFAT.
|
| |
Trends Immunol, 28,
329-332.
|
 |
|
|
|
|
 |
H.J.van der Vliet,
and
E.E.Nieuwenhuis
(2007).
IPEX as a result of mutations in FOXP3.
|
| |
Clin Dev Immunol, 2007,
89017.
|
 |
|
|
|
|
 |
H.P.Kim,
and
W.J.Leonard
(2007).
CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation.
|
| |
J Exp Med, 204,
1543-1551.
|
 |
|
|
|
|
 |
H.Wu,
A.Peisley,
I.A.Graef,
and
G.R.Crabtree
(2007).
NFAT signaling and the invention of vertebrates.
|
| |
Trends Cell Biol, 17,
251-260.
|
 |
|
|
|
|
 |
H.von Boehmer
(2007).
Oral tolerance: is it all retinoic acid?
|
| |
J Exp Med, 204,
1737-1739.
|
 |
|
|
|
|
 |
I.E.Dijke,
J.H.Velthuis,
K.Caliskan,
S.S.Korevaar,
A.P.Maat,
P.E.Zondervan,
A.H.Balk,
W.Weimar,
and
C.C.Baan
(2007).
Intragraft FOXP3 mRNA expression reflects antidonor immune reactivity in cardiac allograft patients.
|
| |
Transplantation, 83,
1477-1484.
|
 |
|
|
|
|
 |
J.Baumgartner,
C.Wilson,
B.Palmer,
D.Richter,
A.Banerjee,
and
M.McCarter
(2007).
Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells.
|
| |
J Surg Res, 141,
72-77.
|
 |
|
|
|
|
 |
J.Bodor,
Z.Fehervari,
B.Diamond,
and
S.Sakaguchi
(2007).
ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells.
|
| |
Eur J Immunol, 37,
884-895.
|
 |
|
|
|
|
 |
J.Larkin,
C.C.Picca,
and
A.J.Caton
(2007).
Activation of CD4+ CD25+ regulatory T cell suppressor function by analogs of the selecting peptide.
|
| |
Eur J Immunol, 37,
139-146.
|
 |
|
|
|
|
 |
J.Wang,
A.Ioan-Facsinay,
E.I.van der Voort,
T.W.Huizinga,
and
R.E.Toes
(2007).
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.
|
| |
Eur J Immunol, 37,
129-138.
|
 |
|
|
|
|
 |
L.E.Mays,
and
Y.H.Chen
(2007).
Maintaining immunological tolerance with Foxp3.
|
| |
Cell Res, 17,
904-918.
|
 |
|
|
|
|
 |
L.Guo,
A.Han,
D.L.Bates,
J.Cao,
and
L.Chen
(2007).
Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains.
|
| |
Proc Natl Acad Sci U S A, 104,
4297-4302.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Wang,
D.Li,
Z.Fu,
H.Li,
W.Jiang,
and
D.Li
(2007).
Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population.
|
| |
BMC Cancer, 7,
173.
|
 |
|
|
|
|
 |
L.Zhang,
and
Y.Zhao
(2007).
The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road.
|
| |
J Cell Physiol, 211,
590-597.
|
 |
|
|
|
|
 |
M.Ahmadzadeh,
P.A.Antony,
and
S.A.Rosenberg
(2007).
IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.
|
| |
J Immunother (1997), 30,
294-302.
|
 |
|
|
|
|
 |
M.Miyara,
and
S.Sakaguchi
(2007).
Natural regulatory T cells: mechanisms of suppression.
|
| |
Trends Mol Med, 13,
108-116.
|
 |
|
|
|
|
 |
M.Ono,
H.Yaguchi,
N.Ohkura,
I.Kitabayashi,
Y.Nagamura,
T.Nomura,
Y.Miyachi,
T.Tsukada,
and
S.Sakaguchi
(2007).
Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.
|
| |
Nature, 446,
685-689.
|
 |
|
|
|
|
 |
M.Podtschaske,
U.Benary,
S.Zwinger,
T.Höfer,
A.Radbruch,
and
R.Baumgrass
(2007).
Digital NFATc2 Activation per Cell Transforms Graded T Cell Receptor Activation into an All-or-None IL-2 Expression.
|
| |
PLoS ONE, 2,
e935.
|
 |
|
|
|
|
 |
M.S.Sundrud,
and
A.Rao
(2007).
Regulatory T-cell gene expression: ChIP'ing away at Foxp3.
|
| |
Immunol Cell Biol, 85,
177-178.
|
 |
|
|
|
|
 |
M.Savignac,
B.Mellström,
and
J.R.Naranjo
(2007).
Calcium-dependent transcription of cytokine genes in T lymphocytes.
|
| |
Pflugers Arch, 454,
523-533.
|
 |
|
|
|
|
 |
N.Cools,
P.Ponsaerts,
V.F.Van Tendeloo,
and
Z.N.Berneman
(2007).
Regulatory T cells and human disease.
|
| |
Clin Dev Immunol, 2007,
89195.
|
 |
|
|
|
|
 |
O.Dienz,
S.M.Eaton,
T.J.Krahl,
S.Diehl,
C.Charland,
J.Dodge,
S.L.Swain,
R.C.Budd,
L.Haynes,
and
M.Rincon
(2007).
Accumulation of NFAT mediates IL-2 expression in memory, but not naïve, CD4+ T cells.
|
| |
Proc Natl Acad Sci U S A, 104,
7175-7180.
|
 |
|
|
|
|
 |
P.Reddy,
and
W.Zou
(2007).
Blocking HDACs boosts regulatory T cells.
|
| |
Nat Med, 13,
1282-1284.
|
 |
|
|
|
|
 |
R.Bommireddy,
and
T.Doetschman
(2007).
TGFbeta1 and Treg cells: alliance for tolerance.
|
| |
Trends Mol Med, 13,
492-501.
|
 |
|
|
|
|
 |
R.H.Medema,
and
B.M.Burgering
(2007).
The X factor: skewing X inactivation towards cancer.
|
| |
Cell, 129,
1253-1254.
|
 |
|
|
|
|
 |
R.H.Prabhala,
and
N.C.Munshi
(2007).
Immune therapies.
|
| |
Hematol Oncol Clin North Am, 21,
1217.
|
 |
|
|
|
|
 |
R.Tao,
E.F.de Zoeten,
E.Ozkaynak,
C.Chen,
L.Wang,
P.M.Porrett,
B.Li,
L.A.Turka,
E.N.Olson,
M.I.Greene,
A.D.Wells,
and
W.W.Hancock
(2007).
Deacetylase inhibition promotes the generation and function of regulatory T cells.
|
| |
Nat Med, 13,
1299-1307.
|
 |
|
|
|
|
 |
R.Tao,
E.F.de Zoeten,
E.Ozkaynak,
L.Wang,
B.Li,
M.I.Greene,
A.D.Wells,
and
W.W.Hancock
(2007).
Histone deacetylase inhibitors and transplantation.
|
| |
Curr Opin Immunol, 19,
589-595.
|
 |
|
|
|
|
 |
R.Y.Lan,
I.R.Mackay,
and
M.E.Gershwin
(2007).
Regulatory T cells in the prevention of mucosal inflammatory diseases: patrolling the border.
|
| |
J Autoimmun, 29,
272-280.
|
 |
|
|
|
|
 |
S.Bandyopadhyay,
N.Soto-Nieves,
and
F.Macián
(2007).
Transcriptional regulation of T cell tolerance.
|
| |
Semin Immunol, 19,
180-187.
|
 |
|
|
|
|
 |
S.C.Vernes,
E.Spiteri,
J.Nicod,
M.Groszer,
J.M.Taylor,
K.E.Davies,
D.H.Geschwind,
and
S.E.Fisher
(2007).
High-throughput analysis of promoter occupancy reveals direct neural targets of FOXP2, a gene mutated in speech and language disorders.
|
| |
Am J Hum Genet, 81,
1232-1250.
|
 |
|
|
|
|
 |
S.Choi,
and
R.H.Schwartz
(2007).
Molecular mechanisms for adaptive tolerance and other T cell anergy models.
|
| |
Semin Immunol, 19,
140-152.
|
 |
|
|
|
|
 |
S.D.Miller,
D.M.Turley,
and
J.R.Podojil
(2007).
Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease.
|
| |
Nat Rev Immunol, 7,
665-677.
|
 |
|
|
|
| |